Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6H39

Yeast 20S proteasome in complex with the peptidic non-covalent binding inhibitor RTS-V5

Summary for 6H39
Entry DOI10.2210/pdb6h39/pdb
DescriptorProteasome subunit alpha type-2, Proteasome subunit beta type-4, Proteasome subunit beta type-5, ... (20 entities in total)
Functional Keywordshydrolase-hydrolase inhibitor complex, proteasome, histone-deacetylase, dual binding inhibitor, binding analysis, hydrolase
Biological sourceSaccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)
More
Total number of polymer chains28
Total formula weight732998.52
Authors
Groll, M.,Hansen, F.K. (deposition date: 2018-07-17, release date: 2018-11-07, Last modification date: 2024-01-17)
Primary citationBhatia, S.,Krieger, V.,Groll, M.,Osko, J.D.,Reßing, N.,Ahlert, H.,Borkhardt, A.,Kurz, T.,Christianson, D.W.,Hauer, J.,Hansen, F.K.
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
J. Med. Chem., 61:10299-10309, 2018
Cited by
PubMed Abstract: Dual- or multitarget drugs have emerged as a promising alternative to combination therapies. Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase (HDAC) inhibitors due to the simultaneous blockage of the ubiquitin degradation and aggresome pathways. Here, we present the design, synthesis, binding modes, and anticancer properties of RTS-V5 as the first-in-class dual HDAC-proteasome ligand. The inhibition of both targets was confirmed by biochemical and cellular assays as well as X-ray crystal structures of the 20S proteasome and HDAC6 complexed with RTS-V5. Cytotoxicity assays with leukemia and multiple myeloma cell lines as well as therapy refractory primary patient-derived leukemia cells demonstrated that RTS-V5 possesses potent and selective anticancer activity. Our results will thus guide the structure-based optimization of dual HDAC-proteasome inhibitors for the treatment of hematological malignancies.
PubMed: 30365892
DOI: 10.1021/acs.jmedchem.8b01487
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.5 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon